Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Identifying therapeutic targets in gastric cancer: the current status and future direction.

Literature DB >> 26373844

Identifying therapeutic targets in gastric cancer: the current status and future direction.

Abstract

Gastric cancer is the third leading cause of cancer-related death worldwide. Our basic understanding of gastric cancer biology falls behind that of many other cancer types. Current standard treatment options for gastric cancer have not changed for the last 20 years. Thus, there is an urgent need to establish novel strategies to treat this deadly cancer. Successful clinical trials with Gleevec in CML and gastrointestinal stromal tumors have set up an example for targeted therapy of cancer. In this review, we will summarize major progress in classification, therapeutic options of gastric cancer. We will also discuss molecular mechanisms for drug resistance in gastric cancer. In addition, we will attempt to propose potential future directions in gastric cancer biology and drug targets.

© The Author 2015. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities: Disease

Keywords: Wnt; cancer stem cell; gastric cancer; hedgehog; targeted therapy

Mesh：

Substances：

Year: 2015 PMID： 26373844 PMCID： PMC4689156 DOI： 10.1093/abbs/gmv084

Source DB: PubMed Journal: Acta Biochim Biophys Sin (Shanghai) ISSN： 1672-9145 Impact factor: 3.848

80 in total

Review 1. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors: A Singh; J Settleman
Journal: Oncogene Date: 2010-06-07 Impact factor: 9.867

Review 2. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.

Authors: Dietrich Keppler
Journal: Handb Exp Pharmacol Date: 2011

3. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.

Authors: Coumaran Egile; Mireille Kenigsberg; Christine Delaisi; Françoise Bégassat; Véronique Do-Vale; Jessica Mestadier; Fabrice Bonche; Tsiala Bénard; Jean-Paul Nicolas; Sandrine Valence; Céline Lefranc; Elisa Francesconi; Christelle Castell; Anne-Marie Lefebvre; Conception Nemecek; Loreley Calvet; Hélène Goulaouic
Journal: Mol Cancer Ther Date: 2014-12-10 Impact factor: 6.261

4. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544

5. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.

Authors: Zhengdeng Lei; Iain Beehuat Tan; Kakoli Das; Niantao Deng; Hermioni Zouridis; Sharon Pattison; Clarinda Chua; Zhu Feng; Yeoh Khay Guan; Chia Huey Ooi; Tatiana Ivanova; Shenli Zhang; Minghui Lee; Jeanie Wu; Anna Ngo; Sravanthy Manesh; Elisabeth Tan; Bin Tean Teh; Jimmy Bok Yan So; Liang Kee Goh; Alex Boussioutas; Tony Kiat Hon Lim; Horst Flotow; Patrick Tan; Steven G Rozen
Journal: Gastroenterology Date: 2013-05-14 Impact factor: 22.682

6. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396

Review 7. Mismatch repair and response to DNA-damaging antitumour therapies.

Authors: M Bignami; I Casorelli; P Karran
Journal: Eur J Cancer Date: 2003-10 Impact factor: 9.162

8. Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer.

Authors: Meiqin Yuan; Yunshan Yang; Wangxia Lv; Zhengbo Song; Haijun Zhong
Journal: Oncol Lett Date: 2014-05-09 Impact factor: 2.967

9. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.

Authors: Y J Liu; D Shen; X Yin; P Gavine; T Zhang; X Su; P Zhan; Y Xu; J Lv; J Qian; C Liu; Y Sun; Z Qian; J Zhang; Y Gu; X Ni
Journal: Br J Cancer Date: 2014-02-11 Impact factor: 7.640

10. New insights into the RNA-based mechanism of action of the anticancer drug 5'-fluorouracil in eukaryotic cells.

Authors: Laura Mojardín; Javier Botet; Luis Quintales; Sergio Moreno; Margarita Salas
Journal: PLoS One Date: 2013-11-01 Impact factor: 3.240

9 in total

1. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.

Authors: Beiqin Yu; Dongsheng Gu; Xiaoli Zhang; Bingya Liu; Jingwu Xie
Journal: J Genet Genomics Date: 2017-07-25 Impact factor: 4.275

2. Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin.

Authors: Yaowei Ai; Qiaohui Zhou; Ling Li; Zhihong Pan; Mingwen Guo; Jingbo Han
Journal: Oncol Lett Date: 2017-12-27 Impact factor: 2.967

3. Identification of a novel YAP-14-3-3ζ negative feedback loop in gastric cancer.

Authors: Bin Zhang; Aihua Gong; Hui Shi; Qingli Bie; Zhaofeng Liang; Peipei Wu; Fei Mao; Hui Qian; Wenrong Xu
Journal: Oncotarget Date: 2017-05-19

4. YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression.

Authors: Zhaoji Pan; Yiqing Tian; Bin Zhang; Xu Zhang; Hui Shi; Zhaofeng Liang; Peipei Wu; Rong Li; Benshuai You; Lunyu Yang; Fei Mao; Hui Qian; Wenrong Xu
Journal: Int J Oncol Date: 2017-08-23 Impact factor: 5.650